HRP20210871T1 - Piridopirimdinonski inhibitori cdk2/4/6 - Google Patents
Piridopirimdinonski inhibitori cdk2/4/6 Download PDFInfo
- Publication number
- HRP20210871T1 HRP20210871T1 HRP20210871TT HRP20210871T HRP20210871T1 HR P20210871 T1 HRP20210871 T1 HR P20210871T1 HR P20210871T T HRP20210871T T HR P20210871TT HR P20210871 T HRP20210871 T HR P20210871T HR P20210871 T1 HRP20210871 T1 HR P20210871T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- methylcyclopentyl
- hydroxy
- Prior art date
Links
- 101150073031 cdk2 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- QIEKHLDZKRQLLN-FOIQADDNSA-N 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F QIEKHLDZKRQLLN-FOIQADDNSA-N 0.000 claims 2
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 claims 2
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 claims 2
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 claims 2
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- FLKRMXAWABTWSH-UHFFFAOYSA-N piperidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCCCC1 FLKRMXAWABTWSH-UHFFFAOYSA-N 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- GUFBYMCWKSZUBS-IIBYNOLFSA-N 6-(2,2-difluoroethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@]1(O)CCC[C@H]1N1C(=O)C(CC(F)F)=CC2=CN=C(NC3CCN(CC3)S(C)(=O)=O)N=C12 GUFBYMCWKSZUBS-IIBYNOLFSA-N 0.000 claims 1
- GUFBYMCWKSZUBS-KKSFZXQISA-N 6-(2,2-difluoroethyl)-8-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@]1(O)CCC[C@@H]1N1C(=O)C(CC(F)F)=CC2=CN=C(NC3CCN(CC3)S(C)(=O)=O)N=C12 GUFBYMCWKSZUBS-KKSFZXQISA-N 0.000 claims 1
- QIEKHLDZKRQLLN-YWZLYKJASA-N 6-(difluoromethyl)-8-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@@H]1[C@@](CCC1)(C)O)F QIEKHLDZKRQLLN-YWZLYKJASA-N 0.000 claims 1
- XVNGVXMJENQILZ-DNVCBOLYSA-N 8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]-6-(trifluoromethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O[C@]1([C@@H](CCC1)N1C(C(=CC2=C1N=C(N=C2)NC1CCN(CC1)S(=O)(=O)C)C(F)(F)F)=O)C XVNGVXMJENQILZ-DNVCBOLYSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (20)
1. Spoj Formule (VI):
[image]
,
ili njegova farmaceutski prihvatljiva sol, naznačen time što:
R2A i R2B su neovisno H, OH ili C1-C4 alkil, uz uvjet da najmanje jedan od R2A i R2B nije H;
R3 je C1-C4 fluoralkil;
R4 je H;
R5A je SO2R7 ili SO2NR8R9;
R7 je C1-C4 alkil; i
R8 i R9 su neovisno H ili C1-C4 alkil.
2. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što ima Formulu (VI-A):
[image]
.
3. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 2, naznačen time što ima Formulu (VI-B):
[image]
.
4. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 2, naznačen time što ima Formulu (VI-C):
[image]
.
5. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je R3 C1-C2 fluoralkil.
6. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 5, naznačen time što je R3 CF2H ili CH2CF2H.
7. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je R7 CH3.
8. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što su R8 i R9 neovisno H ili CH3.
9. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 3, naznačen time što:
jedan od R2A i R2B je OH, a drugi je CH3; ili
jedan od R2A i R2B je OH, a drugi je H; ili
jedan od R2A i R2B je H, a drugi je CH3;
R3 je CF2H ili CH2CF2H;
R4 je H;
R5A je SO2R7; i
R7 je CH3.
10. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što je:
(+)-6-(2,2-difluoretil)-8-[(1R*,2R*)-2-hidroksi-2-metilciklopentil]-2-{[1-(metilsulfonil)piperidin-4-il]amino}pirido[2,3-d]pirimidin-7(8H)-on;
(–)-6-(2,2-difluoretil)-8-[(1R*,2R*)-2-hidroksi-2-metilciklopentil]-2-{[1-(metilsulfonil)piperidin-4-il]amino}pirido[2,3-d]pirimidin-7(8H)-on;
6-(difluormetil)-8-[(1R,2R)-2-hidroksi-2-metilciklopentil]-2-{[1-(metilsulfonil)piperidin-4-il]amino}pirido[2,3-d]pirimidin-7(8H)-on;
(–)-4-({6-(difluormetil)-8-[(1R*,2R*)-2-hidroksi-2-metilciklopentil]-7-okso-7,8-dihidropirido[2,3-d]pirimidin-2-il}amino)-N-metilpiperidin-1-sulfonamid;
(+)-4-({6-(difluormetil)-8-[(1R*,2R*)-2-hidroksi-2-metilciklopentil]-7-okso-7,8-dihidropirido[2,3-d]pirimidin-2-il}amino)-N-metilpiperidin-1-sulfonamid;
8-[(1R,2R)-2-hidroksi-2-metilciklopentil]-2-{[1-(metilsulfonil)piperidin-4-il]amino}-6-(trifluormetil)pirido[2,3-d]pirimidin-7(8H)-on;
6-(difluormetil)-8-[(1S,2S)-2-hidroksi-2-metilciklopentil]-2-{[1-(metilsulfonil)piperidin-4-il]amino}pirido[2,3-d]pirimidin-7(8H)-on;
(–)-4-({6-(difluormetil)-8-[(1R*,2R*)-2-hidroksi-2-metilciklopentil]-7-okso-7,8-dihidropirido[2,3-d]pirimidin-2-il}amino)piperidin-1-sulfonamid; ili
(+)-4-({6-(difluormetil)-8-[(1R*,2R*)-2-hidroksi-2-metilciklopentil]-7-okso-7,8-dihidropirido[2,3-d]pirimidin-2-il}amino)piperidin-1-sulfonamid.
11. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je 6-(difluormetil)-8-[(1R,2R)-2-hidroksi-2-metilciklopentil]-2-{[1-(metilsulfonil)piperidin-4-il]amino}pirido[2,3-d]pirimidin-7(8H)-on.
12. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je:
[image]
.
13. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, kao i farmaceutski prihvatljivi nosač ili pomoćno sredstvo.
14. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je namijenjen upotrebi kao medikament.
15. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je namijenjen upotrebi u liječenju abnormalnog staničnog rasta.
16. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 15, naznačen time što je navedeni abnormalni stanični rast rak.
17. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 16, gdje je rak (a) rak dojke ili rak jajnika; (b) naznačen time što je amplificiran ili hipereksprimiran ciklin E1 (CCNE1) i ciklin E2 (CCNE2); ili (c) i (a) i (b).
18. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačen time što se navedeni spoj primjenjuje uzastopno ili istodobno s najmanje jednim dodatnim farmaceutskim ili medicinskim sredstvom.
19. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 18, naznačen time što je navedeno dodatno farmaceutsko ili medicinsko sredstvo sredstvo protiv raka.
20. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 18, naznačen time što je navedeno dodatno farmaceutsko ili medicinsko sredstvo tamoksifen, docetaksel, paklitaksel, cisplatin, kapecitabin, gemcitabin, vinorelbin, eksemestan, letrozol, fulvestrant, anastrozol ili trastuzumab.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371602P | 2016-08-15 | 2016-08-15 | |
| US201762533347P | 2017-07-17 | 2017-07-17 | |
| EP17752493.1A EP3497103B1 (en) | 2016-08-15 | 2017-07-31 | Pyridopyrimdinone cdk2/4/6 inhibitors |
| PCT/IB2017/054655 WO2018033815A1 (en) | 2016-08-15 | 2017-07-31 | Pyridopyrimdinone cdk2/4/6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210871T1 true HRP20210871T1 (hr) | 2021-07-09 |
Family
ID=59631834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210871TT HRP20210871T1 (hr) | 2016-08-15 | 2021-06-01 | Piridopirimdinonski inhibitori cdk2/4/6 |
Country Status (41)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109803968A (zh) * | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
| JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| JP2020097562A (ja) * | 2018-09-25 | 2020-06-25 | ファイザー・インク | ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020130125A1 (ja) | 2018-12-21 | 2020-06-25 | 第一三共株式会社 | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
| WO2020148635A1 (en) * | 2019-01-17 | 2020-07-23 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| TW202045181A (zh) | 2019-02-15 | 2020-12-16 | 美商英塞特公司 | 細胞週期蛋白依賴性激酶2生物標記物及其用途 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| KR20220003565A (ko) | 2019-04-19 | 2022-01-10 | 화이자 인코포레이티드 | Pah를 치료하기 위한 항증식제 |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020240360A1 (en) * | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
| CN116348458A (zh) | 2019-08-14 | 2023-06-27 | 因赛特公司 | 作为cdk2抑制剂的咪唑基嘧啶基胺化合物 |
| CR20220170A (es) * | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| CN114555600B (zh) * | 2019-10-17 | 2024-03-01 | 辰欣药业股份有限公司 | 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物 |
| CA3164623A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Ｃｄｋ２／４／６阻害剤としての化合物 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| CN113773315A (zh) * | 2020-06-10 | 2021-12-10 | 无锡佰翱得生物科学有限公司 | 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂 |
| WO2021254384A1 (zh) * | 2020-06-17 | 2021-12-23 | 微境生物医药科技(上海)有限公司 | 新型吡啶并[2，3-d]嘧啶-7(8H)-酮衍生物 |
| WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
| KR20230069983A (ko) | 2020-09-15 | 2023-05-19 | 화이자 인코포레이티드 | Cdk4 억제제의 고체 형태 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CA3202355A1 (en) * | 2020-12-22 | 2022-06-30 | Jiping Fu | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN117858879A (zh) * | 2021-01-15 | 2024-04-09 | 南京再明医药有限公司 | Cdk2/4/6抑制剂及其制备方法和应用 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| EP4353724A1 (en) * | 2021-06-09 | 2024-04-17 | TYK Medicines (Zhengzhou), Inc. | Compound as cdk kinase inhibitor and use thereof |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
| WO2023051302A1 (zh) * | 2021-09-29 | 2023-04-06 | 中国医药研究开发中心有限公司 | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| CN118678960A (zh) * | 2021-11-18 | 2024-09-20 | 安可诺瓦治疗公司 | 用于治疗癌症的方法和组合物 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023249968A1 (en) * | 2022-06-22 | 2023-12-28 | Nikang Therapeutics, Inc. | Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| US20240174665A1 (en) * | 2022-08-19 | 2024-05-30 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
| WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
| WO2024173766A1 (en) * | 2023-02-17 | 2024-08-22 | Differentiated Therapeutics, Inc. | Cyclin dependent kinase degraders and methods of use thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| WO1998023613A1 (en) | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| KR20020070520A (ko) | 2000-01-27 | 2002-09-09 | 워너-램버트 캄파니 | 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체 |
| HUP0300136A2 (en) | 2000-03-06 | 2003-05-28 | Warner Lambert Co | 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| JP4064818B2 (ja) | 2001-02-12 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | ６−置換ピリド−ピリミジン類 |
| WO2003062236A1 (en) | 2002-01-22 | 2003-07-31 | Warner-Lambert Company Llc | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| PA8577501A1 (es) * | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| US6951769B2 (en) | 2003-06-04 | 2005-10-04 | Texas Instruments Incorporated | Method for stripping sacrificial layer in MEMS assembly |
| MXPA06000484A (es) | 2003-07-11 | 2006-04-05 | Warner Lambert Co | Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina. |
| JP2007523151A (ja) | 2004-02-18 | 2007-08-16 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| PT1940839E (pt) * | 2005-10-07 | 2013-10-10 | Exelixis Inc | Inibidores de piridopirimidinona pi3k alfa |
| EA016945B1 (ru) * | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| RU2009108006A (ru) | 2006-09-08 | 2010-10-20 | Пфайзер Продактс Инк. (Us) | Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов |
| EA016388B1 (ru) | 2006-09-15 | 2012-04-30 | Пфайзер Продактс Инк. | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| BRPI0810206A2 (pt) * | 2007-04-10 | 2014-10-21 | Exelixis Inc | Método de tratar câncer |
| WO2009132980A1 (en) * | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | Pyrimidinyl pyridone inhibitors of jnk. |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| CN102177161A (zh) | 2008-10-22 | 2011-09-07 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
| TW201300385A (zh) * | 2011-04-08 | 2013-01-01 | Afraxis Inc | 用於治療ｃｎｓ病症和癌症的８－乙基－６－（芳基）吡啶并［２，３－ｄ］嘧啶－７（８ｈ）－酮 |
| UY34044A (es) * | 2011-04-29 | 2012-11-30 | Sanofi Sa | Metodo de tratamiento contra el linfoma con inhibidores de piridopirimidinona de p13k/mtor |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| EP2817308B1 (en) * | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| SG11201505680RA (en) | 2013-02-21 | 2015-09-29 | Pfizer | Solid forms of a selective cdk4/6 inhibitor |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2015084936A1 (en) * | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US9734210B2 (en) | 2014-07-31 | 2017-08-15 | Linkedin Corporation | Personalized search based on searcher interest |
| CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| CN109803968A (zh) * | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
-
2017
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 MX MX2019001849A patent/MX2019001849A/es unknown
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko active IP Right Grant
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja active Active
- 2017-07-31 CN CN202210092651.2A patent/CN114394966B/zh active Active
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en active Application Filing
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en active Active
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh active
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
-
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
-
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
-
2021
- 2021-06-01 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
-
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210871T1 (hr) | Piridopirimdinonski inhibitori cdk2/4/6 | |
| ES2908300T3 (es) | Compuestos de benzoxacepin oxazolidinona y procedimientos de uso | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| RU2015139513A (ru) | Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста | |
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| ES2674705T3 (es) | Compuestos heteroaromáticos como moduladores de la quinasa PI3 | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| HRP20190814T1 (hr) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci uporabe | |
| HRP20140953T1 (hr) | Morfolino pirimidini i njihova uporaba za lijeäśenje | |
| BR112015023705A8 (pt) | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) | |
| NZ711948A (en) | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| JP2017511360A5 (hr) | ||
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| PH12014502040A1 (en) | Heterocyclyl compounds | |
| BR112014029708A2 (pt) | composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina | |
| IN2014MN01919A (hr) | ||
| BR112016022342A8 (pt) | derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| BR112020007593A2 (pt) | derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
| SV2016005226A (es) | Derivados de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis |